Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:ADCT
DateTimeSourceHeadlineSymbolCompany
01/02/20254:05PMPR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
12/30/20244:30PMPR Newswire (US)ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell LymphomaNYSE:ADCTADC Therapeutics SA
12/11/20247:30AMPR Newswire (US)ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaNYSE:ADCTADC Therapeutics SA
12/09/20248:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
12/09/20248:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
12/09/20248:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
12/09/20247:30AMPR Newswire (US)ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaNYSE:ADCTADC Therapeutics SA
12/06/20247:30AMPR Newswire (US)ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical TrialNYSE:ADCTADC Therapeutics SA
12/02/20244:30PMPR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
11/07/202410:44AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
11/07/20247:54AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
11/07/20247:30AMPR Newswire (US)ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdateNYSE:ADCTADC Therapeutics SA
11/05/20249:47AMPR Newswire (US)ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual MeetingNYSE:ADCTADC Therapeutics SA
11/04/20247:15AMPR Newswire (US)ADC Therapeutics to Present at November Investor ConferencesNYSE:ADCTADC Therapeutics SA
11/01/20244:05PMPR Newswire (US)ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
10/31/20247:15AMPR Newswire (US)ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024NYSE:ADCTADC Therapeutics SA
10/01/20244:05PMGlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
09/23/20244:39PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:ADCTADC Therapeutics SA
09/23/20244:35PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:ADCTADC Therapeutics SA
09/13/20244:16PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNYSE:ADCTADC Therapeutics SA
09/03/20244:05PMGlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
09/03/20247:15AMGlobeNewswire Inc.ADC Therapeutics to Present at Upcoming Investor ConferencesNYSE:ADCTADC Therapeutics SA
08/14/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:ADCTADC Therapeutics SA
08/06/20244:26PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NYSE:ADCTADC Therapeutics SA
08/06/202410:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
08/06/20247:37AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
08/06/20247:30AMGlobeNewswire Inc.ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateNYSE:ADCTADC Therapeutics SA
08/01/20244:05PMGlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
07/30/20247:15AMGlobeNewswire Inc.ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024NYSE:ADCTADC Therapeutics SA
07/08/20242:00AMGlobeNewswire Inc.Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentNYSE:ADCTADC Therapeutics SA
 Showing the most relevant articles for your search:NYSE:ADCT

Your Recent History

Delayed Upgrade Clock